Head and Neck Squamous Cell Carcinoma
Conditions
Keywords
Sentinel lymph node identification, Magnetic resonance imaging, Superparamagnetic iron oxide, Oral cancer
Brief summary
To explore the feasibility of sentinel lymph node identification by SPIO injection followed by MRI in head-and-neck cancer patients.
Interventions
DIAGNOSTIC_TESTSPIO-enhanced MRI
SPIO is peritumorally injected. A T2\*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
Sponsors
Radboud University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged \>18 years. * Patients with histopathologically proven cT1-2N0M0 squamous cell carcinoma of the oral cavity. * Patients planned to undergo routine sentinel node biopsy with 99mTc-radioisotope and SPECT-CT. * Patient provided written informed consent.
Exclusion criteria
* Patients who underwent previous surgery or radiotherapy to the neck. * Contra-indications to SPIO (Hypersensitivity to iron oxide or dextran compounds, Presence of iron overload disease (hereditary hemochromatosis, hemosiderosis, chronic hemolytic anemia (e.g. thalassemia, sickle cell anemia)) * Contra-indications to MRI: Epilepsy, Claustrophobia, Metallic splinters, Pacemaker, pacemaker wires or implanted defibrillator, Implanted magnets in jaw, Metallic Arterial clips (carotid arteries), Pregnancy, Auditory implant, neurogenic bladder stimulator, insulin pump, neurostimulator, baclofen pump, Metallic tissue expander after mastectomy, Cochlear implant, Metallic braces, Other foreign bodies implanted * Unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MR (artefact) finetuning for optimization of SPIO dose and timing of MRI | 2 months | The first two patients will receive a dose of 0.012 ml SPIO. MR-images will be assessed. If this dose provides satisfactory MR-images (good visualization of lymph nodes without disturbing artefacts), subsequent patients will receive the same dose. If the artefact is too large, the dose will be decreased. If visualization is poor, the dose will be increased. The procedure will be repeated with adjusted doses each time in two patients until satisfactory MR-images are obtained. The investigators have established timing of MRI 1 hour after SPIO injection. It is assumed that after this time interval SPIO particles have had sufficient time to migrate to the SNs and to be taken up. However, if this interval appears to be too long because 'too many' SNs are visualized the time interval will be shortened. If this interval appears to be too short since no or too little SNs are visualized because SPIO uptake has not taken place yet, the time interval will be lengthened. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Localization of sentinel lymph nodes detected by conventional 99mTC-nanocollloid injection and SPECT-CT and by SPIO injection and MRI | 1 year | SPIO-enhanced MR-images and SPECT-CT images are compared to investigate whether SPIO-enhanced MRI detects the same sentinel lymph nodes as SPECT-CT. |
| Comparison of SPIO distribution within a lymph node on MR-images and histopathological staining. | 1 year | SNs will be localized on T2\* weighted SPIO-enhanced in vivo MR-images by a radiologist. Lymph node status will be assessed based on signal intensity. All surgically removed lymph nodes are embedded in a tissue cassette. Histopathological analysis of these lymph nodes includes multiple sectioning, HE staining, immunohistochemistry and iron staining. The MR-images are compared to the pathology slices to see whether the MR signal intensity pattern matches the benign/malignant structure of the lymph node. |
Countries
Netherlands
Contacts
Primary ContactD.A.J.J. Driessen, MD
Outcome results
None listed